<unk>  has been approved to treat influenza in Japan. It is, however, only indicated for novel influenza (strains that cause more severe disease) rather than seasonal influenza. As of 2020, the probability of resistance developing appears low.
Favipiravir
Balapiravir
Odalasvir
Ledipasvir
Telaprevir
Molnupiravir
Taribavirin
Saquinavir